Research ArticleOriginal Article
Open Access

Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates

Mohammad A. Alfhili, Irfan Ahmad, Yasser Alraey, Abdulaziz Alangari, Taha Alqahtani and Ayed A. Dera
Saudi Medical Journal November 2022, 43 (11) 1224-1233; DOI: https://doi.org/10.15537/smj.2022.43.11.20220446

References

  1. 1.↵
    1. File TM, Jr.,
    2. Niederman MS.
    Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 993–1016, xi.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Croxall G,
    2. Weston V,
    3. Joseph S,
    4. Manning G,
    5. Cheetham P,
    6. McNally A.
    Increased human pathogenic potential of Escherichia coli from polymicrobial urinary tract infections in comparison to isolates from monomicrobial culture samples. J Med Microbiol 2011; 60: 102–109.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Alqasim A,
    2. Abu Jaffal A,
    3. Alyousef AA.
    Prevalence of multidrug resistance and extended-spectrum beta-lactamase carriage of clinical uropathogenic Escherichia coli isolates in Riyadh, Saudi Arabia. Int J Microbiol 2018; 2018: 3026851.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Dera AA,
    2. Ahmad I,
    3. Rajagopalan P,
    4. Shahrani MA,
    5. Saif A,
    6. Alshahrani MY, et al.
    Synergistic efficacies of thymoquinone and standard antibiotics against multi-drug resistant isolates. Saudi Med J 2021; 42: 196–204.
    OpenUrl
  5. 5.↵
    1. Xu K,
    2. Wang P,
    3. Wang L,
    4. Liu C,
    5. Xu S,
    6. Cheng Y, et al.
    Quinone derivatives from the genus Rubia and their bioactivities. Chem Biodivers 2014; 11: 341–363.
    OpenUrl
  6. 6.↵
    1. Shukla S,
    2. Wu CP,
    3. Nandigama K,
    4. Ambudkar SV.
    The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther 2007; 6: 3279–3286.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Liu Y,
    2. Cai Y,
    3. He C,
    4. Chen M,
    5. Li H.
    Anticancer properties and pharmaceutical applications of plumbagin: A review. Am J Chin Med 2017; 45: 423–441.
    OpenUrl
  8. 8.↵
    1. Hafeez BB,
    2. Zhong W,
    3. Mustafa A,
    4. Fischer JW,
    5. Witkowsky O,
    6. Verma AK.
    Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCepsilon, Stat3 and neuroendocrine markers. Carcinogenesis 2012; 33: 2586–2592.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Dissanayake D,
    2. Perera D,
    3. Keerthirathna LR,
    4. Heendeniya S,
    5. Anderson RJ,
    6. Williams DE, et al.
    Antimicrobial activity of Plumbago indica and ligand screening of plumbagin against methicillin-resistant Staphylococcus aureus. J Biomol Struct Dyn 2020; 40: 3273–3284.
    OpenUrl
  10. 10.↵
    1. Sunil C,
    2. Duraipandiyan V,
    3. Agastian P,
    4. Ignacimuthu S.
    Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats. Food Chem Toxicol 2012; 50: 4356–4363.
    OpenUrlPubMed
  11. 11.
    1. Likhitwitayawuid K,
    2. Kaewamatawong R,
    3. Ruangrungsi N,
    4. Krungkrai J.
    Antimalarial naphthoquinones from Nepenthes thorelii. Planta Med 1998; 64: 237–241.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Fournet A,
    2. Angelo A,
    3. Munoz V,
    4. Roblot F,
    5. Hocquemiller R,
    6. Cave A.
    Biological and chemical studies of Pera benensis, a Bolivian plant used in folk medicine as a treatment of cutaneous leishmaniasis. J Ethnopharmacol 1992; 37: 159–164.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. de Paiva SR,
    2. Figueiredo MR,
    3. Aragao TV,
    4. Kaplan MA.
    Antimicrobial activity in vitro of plumbagin isolated from Plumbago species. Mem Inst Oswaldo Cruz. 2003; 98: 959–961.
    OpenUrlPubMedWeb of Science
  14. 14.↵
    1. Nair SV,
    2. Baranwal G,
    3. Chatterjee M,
    4. Sachu A,
    5. Vasudevan AK,
    6. Bose C, et al.
    Antimicrobial activity of plumbagin, a naturally occurring naphthoquinone from Plumbago rosea, against Staphylococcus aureus and Candida albicans. Int J Med Microbiol 2016; 306: 237–248.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Periasamy H,
    2. Iswarya S,
    3. Pavithra N,
    4. Senthilnathan S,
    5. Gnanamani A.
    In vitro antibacterial activity of plumbagin isolated from Plumbago zeylanica L. against methicillin-resistant Staphylococcus aureus. Lett Appl Microbiol 2019; 69: 41–49.
    OpenUrl
  16. 16.
    Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. 28th ed. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2018.
  17. 17.↵
    1. Magaldi S,
    2. Mata-Essayag S,
    3. Hartung de Capriles C,
    4. Perez C,
    5. Colella MT,
    6. Olaizola C, et al.
    Well diffusion for antifungal susceptibility testing. Int J Infect Dis 2004; 8: 39–45.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Wei JR,
    2. Krishnamoorthy V,
    3. Murphy K,
    4. Kim JH,
    5. Schnappinger D,
    6. Alber T, et al.
    Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A 2011; 108: 4176–4181.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Zhang L,
    2. Xu J,
    3. Xu J,
    4. Zhang H,
    5. He L,
    6. Feng J.
    TssB is essential for virulence and required for type VI secretion system in Ralstonia solanacearum. Microb Pathog 2014; 74: 1–7.
    OpenUrlCrossRefPubMed
  20. 20.
    1. Cermak P,
    2. Olsovska J,
    3. Mikyska A,
    4. Dusek M,
    5. Kadleckova Z,
    6. Vanicek J, et al.
    Strong antimicrobial activity of xanthohumol and other derivatives from hops (Humulus lupulus L.) on gut anaerobic bacteria. APMIS 2017; 125: 1033–1038.
    OpenUrl
  21. 21.↵
    1. Mbaveng AT,
    2. Sandjo LP,
    3. Tankeo SB,
    4. Ndifor AR,
    5. Pantaleon A,
    6. Nagdjui BT, et al.
    Antibacterial activity of nineteen selected natural products against multi-drug resistant Gram-negative phenotypes. Springerplus 2015; 4: 823.
    OpenUrl
  22. 22.↵
    1. Pinault L,
    2. Chabriere E,
    3. Raoult D,
    4. Fenollar F.
    Direct identification of pathogens in urine by use of a specific matrix-assisted laser desorption ionization-time of flight spectrum database. J Clin Microbiol 2019; 57.
  23. 23.↵
    1. Hur J,
    2. Lee A,
    3. Hong J,
    4. Jo WY,
    5. Cho OH,
    6. Kim S, et al.
    Staphylococcus saprophyticus bacteremia originating from urinary tract infections: A case report and literature review. Infect Chemother 2016; 48: 136–139.
    OpenUrl
  24. 24.↵
    1. Karpman E,
    2. Kurzrock EA.
    Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol 2004; 172: 448–453.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Makvana S,
    2. Krilov LR.
    Escherichia coli Infections. Pediatr Rev 2015; 36: 167–170; quiz 71.
    OpenUrlFREE Full Text
  26. 26.↵
    1. Alqasim A.
    Colistin-resistant Gram-genative bacteria in Saudi Arabia: A literature review. J King Saud Univ Sci 2021; 33: 101610.
    OpenUrl
  27. 27.↵
    Carbapenems. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD) 2012.
  28. 28.↵
    1. Tong SY,
    2. Davis JS,
    3. Eichenberger E,
    4. Holland TL,
    5. Fowler VG
    , Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28: 603–661.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Pragman AA,
    2. Kuskowski MA,
    3. Abraham JM,
    4. Filice GA.
    Infectious disease consultation for Staphylococcus aureus bacteremia improves patient management and outcomes. Infect Dis Clin Pract (Baltim Md) 2012; 20: 261–267.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Chong YP,
    2. Moon SM,
    3. Bang KM,
    4. Park HJ,
    5. Park SY,
    6. Kim MN, et al.
    Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother 2013; 57: 1150–1156.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Moise PA,
    2. North D,
    3. Steenbergen JN,
    4. Sakoulas G.
    Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9: 617–624.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Arti H,
    2. Mousapour A,
    3. Alavi SM.
    The effect of intravenous dexamethasone in the treatment of septic arthritis. Pak J Med Sci 2014; 30: 955–957.
    OpenUrl
  33. 33.↵
    1. Jahansepas A,
    2. Aghazadeh M,
    3. Rezaee MA,
    4. Hasani A,
    5. Sharifi Y,
    6. Aghazadeh T, et al.
    Occurrence of Enterococcus faecalis and Enterococcus faecium in various clinical infections: detection of their drug resistance and virulence determinants. Microb Drug Resist 2018; 24: 76–82.
    OpenUrl
  34. 34.↵
    1. Sukumaran V,
    2. Cosh J,
    3. Thammavong A,
    4. Kennedy K,
    5. Ong CW.
    Vancomycin dependent Enterococcus: an unusual mutant? Pathology 2019; 51: 318–320.
    OpenUrl
  35. 35.↵
    1. Ch’ng JH,
    2. Chong KKL,
    3. Lam LN,
    4. Wong JJ,
    5. Kline KA.
    Biofilm-associated infection by enterococci. Nat Rev Microbiol 2019; 17: 82–94.
    OpenUrlCrossRef
  36. 36.↵
    1. Li S,
    2. Konstantinov SR,
    3. Smits R,
    4. Peppelenbosch MP.
    Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med 2017; 23: 18–30.
    OpenUrlCrossRef
  37. 37.↵
    1. Slobodnikova L,
    2. Fialova S,
    3. Rendekova K,
    4. Kovac J,
    5. Mucaji P.
    Antibiofilm activity of plant polyphenols. Molecules 2016; 21: 1717.
    OpenUrl
  38. 38.↵
    1. Velammal SP,
    2. Devi TA,
    3. Amaladhas TP. Antioxidant
    , antimicrobial and cytotoxic activities of silver and gold nanoparticles synthesized using Plumbago zeylanica bark. J Nanostructure Chem 2016; 6: 247–260.
    OpenUrl
  39. 39.↵
    PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; PubChem Compound Summary for CID 10205, Plumbagin. [Updated 2004; cited 2022 Oct 25]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Plumbagin
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords